Indegene Limited — Investor Meet, 04-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Indegene reported Q3 FY26 revenue of INR 942.1 Cr, up 30.8% year-on-year. Adjusted EBITDA margin was 18.5%, with PAT at INR 102.6 Cr. Excluding BioPharm, revenue grew 18.3% year-on-year. The company added 12 new customers exceeding $1 million in value, now totaling 52. Seven large deals, each over $1 million ACV, were won across three accounts, including multi-year, multi-million TCV partnerships leveraging AI for omnichannel orchestration and commercialization. Management sees AI as a significant growth driver, facilitating centralization and expanding service offerings. BioPharm integration is progressing well. Indegene anticipates EBITDA margins to stabilize, then improve sequentially from Q1 FY27, targeting approximately 20% over 6-8 quarters. The outlook conveys confidence in future growth and profitability.